Hao Xinyu, Cheng Shuai, Jiang Bo, Xin Shijie
Department of Vascular Surgery, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, China.
Key Laboratory of Pathogenesis, Prevention and Therapeutics of Aortic Aneurysm, Shenyang, Liaoning, China.
Front Cardiovasc Med. 2022 Dec 15;9:961991. doi: 10.3389/fcvm.2022.961991. eCollection 2022.
Acute aortic dissection (AAD) is a cardiovascular disease that manifests suddenly and fatally. Due to the lack of specific early symptoms, many patients with AAD are often overlooked or misdiagnosed, which is undoubtedly catastrophic for patients. The particular pathogenic mechanism of AAD is yet unknown, which makes clinical pharmacological therapy extremely difficult. Therefore, it is necessary and crucial to find and employ unique biomarkers for Acute aortic dissection (AAD) as soon as possible in clinical practice and research. This will aid in the early detection of AAD and give clear guidelines for the creation of focused treatment agents. This goal has been made attainable over the past 20 years by the quick advancement of omics technologies and the development of high-throughput tissue specimen biomarker screening. The primary histology data support and add to one another to create a more thorough and three-dimensional picture of the disease. Based on the introduction of the main histology technologies, in this review, we summarize the current situation and most recent developments in the application of multi-omics technologies to AAD biomarker discovery and emphasize the significance of concentrating on integration concepts for integrating multi-omics data. In this context, we seek to offer fresh concepts and recommendations for fundamental investigation, perspective innovation, and therapeutic development in AAD.
急性主动脉夹层（AAD）是一种突发性致命心血管疾病。由于缺乏特异性早期症状，许多AAD患者常被忽视或误诊，这对患者而言无疑是灾难性的。AAD独特的致病机制尚不清楚，这使得临床药物治疗极具难度。因此，在临床实践和研究中尽快找到并应用急性主动脉夹层（AAD）的独特生物标志物非常必要且至关重要。这将有助于AAD的早期检测，并为开发针对性治疗药物提供明确指导。在过去20年里，组学技术的快速发展和高通量组织标本生物标志物筛选技术的开发使这一目标得以实现。主要组织学数据相互支持、相互补充，从而形成更全面、更立体的疾病图景。基于对主要组织学技术的介绍，在本综述中，我们总结了多组学技术在AAD生物标志物发现应用方面的现状和最新进展，并强调了专注于整合多组学数据的整合概念的重要性。在此背景下，我们旨在为AAD的基础研究、前瞻性创新和治疗开发提供新的概念和建议。
